OKYO Pharma Adds Top Ophthalmologists to Scientific Advisory Board
Ticker: OKYO · Form: 6-K · Filed: Jan 31, 2024 · CIK: 1849296
Complexity: simple
Sentiment: bullish
Topics: advisory-board, clinical-trials, biotech, drug-development
TL;DR
**OKYO Pharma just stacked its advisory board with top eye doctors, boosting confidence in its dry eye drug OK-101.**
AI Summary
OKYO Pharma Ltd. announced on January 31, 2024, that three distinguished ophthalmologists, Victor Perez, M.D., Anat Galor, M.D., and Mark Milner, M.D., have joined its Scientific Advisory Board. This move follows positive safety and efficacy results from the company's Phase 2 trial of OK-101, a drug being developed for dry eye disease and neuropathic corneal pain. This matters to investors because the expertise of these corneal surgeons from institutions like Bascom Palmer Eye Institute will guide the clinical development of OK-101, potentially accelerating its path to market and increasing its chances of success.
Why It Matters
Adding leading experts to the Scientific Advisory Board can significantly strengthen the clinical development strategy for OK-101, potentially de-risking the drug's path through trials and towards commercialization.
Risk Assessment
Risk Level: medium — While adding experts is positive, the company's primary drug, OK-101, is still in clinical development, which inherently carries significant regulatory and trial risks.
Analyst Insight
A smart investor would view this as a positive development, indicating stronger guidance for OK-101's clinical trials, and might consider further research into OK-101's market potential and the company's overall pipeline.
Key Players & Entities
- OKYO Pharma LTD (company) — the registrant announcing the advisory board additions
- Victor Perez, M.D. (person) — distinguished ophthalmologist joining the Scientific Advisory Board from Bascom Palmer Eye Institute
- Anat Galor, M.D. (person) — distinguished ophthalmologist joining the Scientific Advisory Board from Bascom Palmer Eye Institute
- Mark Milner, M.D. (person) — distinguished ophthalmologist joining the Scientific Advisory Board from Goldman Eye in Palm Beach Gardens, Florida
- OK-101 (other) — the drug in Phase 2 trial for dry eye disease and neuropathic corneal pain
- Bascom Palmer Eye Institute (other) — institution where Dr. Perez and Dr. Galor are from
- Goldman Eye (other) — institution where Dr. Milner is from
- January 31, 2024 (date) — date of the 6-K filing and announcement
Forward-Looking Statements
- The addition of these key opinion leaders will likely accelerate the clinical development timeline for OK-101. (OK-101) — medium confidence, target: 2025-12-31
- OKYO Pharma's stock price will see a short-term positive reaction due to increased investor confidence. (OKYO Pharma Ltd) — low confidence, target: 2024-02-29
FAQ
What is the primary purpose of OKYO Pharma's 6-K filing on January 31, 2024?
The primary purpose of OKYO Pharma's 6-K filing on January 31, 2024, is to announce that distinguished ophthalmologists Victor Perez, M.D., Anat Galor, M.D., and Mark Milner, M.D., have joined its Scientific Advisory Board following positive Phase 2 trial results for OK-101.
Which specific drug is the focus of the new Scientific Advisory Board's expertise?
The new Scientific Advisory Board's expertise will specifically advise OKYO's management on the clinical development of OK-101 for the treatment of dry eye disease and neuropathic corneal pain.
What were the recent results that preceded the expansion of the Scientific Advisory Board?
The expansion of the Scientific Advisory Board followed positive safety and efficacy results in OKYO Pharma's Phase 2 trial of OK-101.
From which institutions do the newly appointed Scientific Advisory Board members hail?
Victor Perez, M.D. and Anat Galor, M.D. are both from the Bascom Palmer Eye Institute, while Mark Milner, M.D. is from the Goldman Eye in Palm Beach Gardens, Florida.
What is the significance of the information in Exhibit 99.1, as stated in the filing?
The information in Exhibit 99.1 is being furnished and shall not be deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934, unless expressly set forth by specific reference.
Filing Stats: 396 words · 2 min read · ~1 pages · Grade level 12.2 · Accepted 2024-01-31 07:00:20
Filing Documents
- form6-k.htm (6-K) — 20KB
- ex99-1.htm (EX-99.1) — 21KB
- ex99-1_001.jpg (GRAPHIC) — 78KB
- 0001493152-24-004405.txt ( ) — 150KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: January 31, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 News Announcement, dated January 31, 2024 4